| Company
| Exchange
| Symbol
| Last price
|
| Quote change
| Market cap
|
|
|
Pharmasset, Inc.
| NASDAQ
|
VRUS
|
0.0000
|
|
|
|
|
|
Pharmasset, Inc. is a clinical-stage pharmaceutical company focused on
discovering, developing, and commercializing novel drugs to treat viral
infections.
| |
| |
|
|
Idenix Pharmaceuticals Inc
| NASDAQ
|
IDIX
|
4.17
|
|
+0.02
(0.48%)
| 558.62M
|
|
|
Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in
the discovery and development of drugs for the treatment of human viral ...
| |
| |
|
|
Gilead Sciences, Inc.
| NASDAQ
|
GILD
|
55.53
|
|
-0.40
(-0.72%)
| 84.70B
|
|
|
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company
that discovers, develops and commercializes medicines.
| |
| |
|
|
PHARMASSET INC DL-,001
| FRA
|
BW6
|
105.70
|
|
|
|
|
|
|
|
|
GILEAD SCIENCES DL-,001
| FRA
|
GIS
|
43.00
|
|
-0.70
(-1.61%)
|
|
|
|
|
|
|
IDENIX PHARMACEUT.DL-,001
| FRA
|
NO9
|
3.08
|
|
-0.21
(-6.35%)
|
|
|
|
|
|
|
GILEAD SCIENCES DL-,001
| ETR
|
GIS
|
43.30
|
|
-1.18
(-2.65%)
|
|
|
|
|
|
|
PerkinElmer, Inc.
| NYSE
|
PKI
|
31.64
|
|
-0.18
(-0.57%)
| 3.54B
|
|
|
PerkinElmer, Inc. is a provider of technology, services and solutions to the
diagnostics, research, environmental, industrial and laboratory services ...
| |
| |
|
|
Qiagen NV
| NASDAQ
|
QGEN
|
18.87
|
|
+0.19
(1.02%)
| 4.42B
|
|
|
Provides genetically oriented technlogy. The Company provides enabling
technologies and products for separating and purifying nucleic acids (DNA and
RNA).
| |
| |
|
|
Qiagen NV
| FRA
|
QIA
|
14.47
|
|
-0.21
(-1.41%)
| 3.39B
|
|
|
Provides genetically oriented technlogy. The Company provides enabling
technologies and products for separating and purifying nucleic acids (DNA and
RNA).
| |
| |
|
|
Qiagen NV
| ETR
|
QIA
|
14.49
|
|
-0.17
(-1.16%)
| 3.39B
|
|
|
Provides genetically oriented technlogy. The Company provides enabling
technologies and products for separating and purifying nucleic acids (DNA and
RNA).
| |
| |
|
|
PERKINELMER INC. DL 1
| FRA
|
PKN
|
24.54
|
|
-0.40
(-1.60%)
|
|
|
|
|
|
|
Bristol Myers Squibb Co.
| NYSE
|
BMY
|
46.73
|
|
+0.33
(0.71%)
| 76.76B
|
|
|
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development,
licensing, manufacturing, marketing, distribution and sale of biopharmaceutical
...
| |
| |
|
|
Helicos BioSciences Corp.
| OTCMKTS
|
HLCSQ
|
0.0035
|
|
0.0000
(0.00%)
| 304,615.00
|
|
|
Helicos Biosciences Corporation is a United States-based life science company.
The Company develops genetic technologies for the research, drug discovery ...
| |
| |
|
|
Marina Biotech, Inc.
| OTCMKTS
|
MRNA
|
0.255
|
|
0.000
(0.04%)
| 4.18M
|
|
|
Marina Biotech, Inc. is a biotechnology company focused on the discovery,
development and commercialization of nucleic acid-based therapies utilizing gene
...
| |
| |
|
|
Bristol Myers Squibb Co.
| NYSE
|
BMY-
|
566.10
|
|
0.00
(0.00%)
| 75.68B
|
|
|
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development,
licensing, manufacturing, marketing, distribution and sale of biopharmaceutical
...
| |
| |
|
|
Meridian Bioscience, Inc.
| NASDAQ
|
VIVO
|
21.63
|
|
-0.08
(-0.37%)
| 895.83M
|
|
|
... polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (
qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by
...
| |
| |
|
|
Enzo Biochem, Inc.
| NYSE
|
ENZ
|
2.25
|
|
0.00
(-0.04%)
| 88.56M
|
|
|
Enzo Biochem, Inc. (Enzo), is an integrated life sciences and biotechnology
company. Enzo has three segments: Enzo Clinical Labs, Enzo Life Sciences, ...
| |
| |
|
|
Enanta Pharmaceuticals Inc
| NASDAQ
|
ENTA
|
19.70
|
|
-0.36
(-1.79%)
| 331.68M
|
|
|
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology
company. The Company uses its chemistry-driven approach and drug discovery ...
| |
| |
|
|
BRISTOL-MYERS SQUIBBDL-10
| FRA
|
BRM
|
35.50
|
|
-1.00
(-2.74%)
|
|
|
|
|
|
